tweetindex
PT

Shariq Shamim ✓

@ShariqShamimMD · Virginia, USA 🇺🇸-🇮🇳 · joined 11 Nov 2017

Interventional Cardiologist, Cath Lab Director #CHIP #CTO #TAVR #PERT #imagefirst tweets personal views ≠medical advise AFMC-O2 उद्यमेनैव हि सिध्यन्ति

22 746Followers
1 425Following
17 082Posts total
179.3KViews on collected posts

Posts recentes

At this point, Tesla’s Full Self-Driving technology is advanced enough that driving a car feels like a chore. Hardware 4 with FSD 14.X. If you have a hectic commute, try FSD, your stress level will decrease significantly. https://t.co/FDkOfc0IrO
4.7K views · 46 likes · 2 reposts · 6 replies Open on X →
Great summery of trials focused on plaque regression: 4.9K views · 8 likes · 2 reposts · 1 replies Open on X →
🚨 Cardiology dogma says plaque only builds. It never breaks down. Nine imaging trials from 2004 to 2023 prove that dogma wrong. "But the data says otherwise." And no, this is not just theory. This is IVUS, OCT, and NIRS imaging inside real coronary arteries. I am a https://t.
31.8K views · 239 likes · 54 reposts · 22 replies Open on X →
Are we going to start DOAC post TAVR not DAPT? @djc795 12.1K views · 31 likes · 7 reposts · 10 replies Open on X →
Presented at #ESCCongress from @JAMA_current: After #TranscatheterAorticValveImplant, factor Xa inhibitor non–vitamin K antagonist oral anticoagulant monotherapy reduced hypoattenuated leaflet thickening vs acetylsalicylic acid monotherapy. https://t.co/aLY3mdBmL8 https://t.co
14.4K views · 27 likes · 12 reposts · 2 replies Open on X →
@ShariqShamimMD Beg to differ - Why not? Is there any trial evidence showing ARBs are superior to ACEi? All head-to-head trials are non-inferior at best. Post-MI with LV dysfunction / HF: • SAVE (captopril vs placebo): 19% relative reduction in all-cause mortality • AIRE (rami 2.6K views · 16 likes · 3 reposts · 3 replies Open on X →
@ShariqShamimMD I use ARB always exclusively because it’s an easy transition to ARNI 2.6K views · 12 likes · 0 reposts · 0 replies Open on X →
@ShariqShamimMD No RCT trial has ever demonstrated mortality benfit for ARB in heart failure. Conversely huge mortality benefits seen for ACEi in HF RCTs. Trial evidence is much stronger for ACEi than ARB. 5.7K views · 44 likes · 1 reposts · 5 replies Open on X →
Why do we still use ACEi as compared to ARB? Similar if. It same benefits for cardiovascular and renal protection. No one knows who will get ACEi Angioedema. Why not just use ARB only? 87.2K views · 247 likes · 10 reposts · 26 replies Open on X →
More data to support BiVal as default AC during STEMI intervention. Are we all going to move to BiVal from Heparin during STEMI as it’s class IA 2025 ACC/AHA to reduce risk of death? #cardiotwitter #CardioX 4.1K views · 11 likes · 3 reposts · 2 replies Open on X →
In BRIGHT-4 (n=6016 randomized), bivalirudin + a 2-4h infusion ↓ mortality & major bleeding during primary PCI in STEMI c/w UFH (Lancet). At ESC/JACC today, in a prespecified substudy, the survival and bleeding benefits extended to low as well as high bleeding-risk pts. https://t
9.2K views · 50 likes · 12 reposts · 2 replies Open on X →

Em comparação com contas do mesmo porte

11 posts dos últimos 90 dias, ao lado da faixa de 10K–100K seguidores. aparece para muita gente, mas poucos desses espectadores reagem.

Mediana de visualizações5 709esta conta924mediana para 10K–100K
Alcance, %25.10%esta conta3.62%mediana para 10K–100K
Engajamento, %0.46%esta conta1.52%mediana para 10K–100K
MétricaEsta contaMediana para 10K–100KProporção
Mediana de visualizações por post5 7099246.18×
Alcance (visualizações ÷ seguidores)25.10%3.62%6.93×
Taxa de engajamento0.46%1.52%0.30×

Outras contas desta faixa →   Comparar com outra conta →   Como estas referências são construídas →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

9.2K28 Aug
4.1K
87.2K
5.7K
2.6K29 Aug
2.6K
14.4K30 Aug
12.1K
31.8K7 Sep
4.9K
4.7K12 Sep

Last 11 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.70%28 Aug
0.39%
0.32%
0.88%
0.45%29 Aug
0.86%
0.29%30 Aug
0.40%
0.99%7 Sep
0.22%
1.14%12 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes52.1%731 in total
Reposts7.5%106 in total
Replies5.6%79 in total
Quotes0.1%1 in total
Bookmarks34.7%487 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Contas semelhantes